graph Evidence gap map comparisons
atezolizumab based treatmentImmune checkpoint association
atezolizumab alone atezolizumab plus cometinib durvalumab plus tremelimumab
mCRC - 2nd line (L2) 3       
Comparator:  vs regorafenib;   vs BSC; 
Risk of bias:  low;   some concerns;   high;  NA;